We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Stronger Together: Eliminating Racial Healthcare Inequities

By Jen A. Miller (AACC)
Posted on 07 Jul 2023
Print article
Illustration
Illustration
Health equity remains an important emphasis throughout healthcare, including in laboratory medicine. But recognizing disparities in healthcare—and developing solutions to make sure that everyone has equal access to cutting-edge medicine—will only be realized if laboratorians play an active role.

The session, Stronger Together: Eliminating Racial Healthcare Inequities by Mitigating Systemic Racism, by Drs. Christina Pierre, Esa Davis, and Octavia Peck Palmer will focus on racism as a key driver of health inequities, specifically how structural racism influences social determinants of health that lead to poorer health and well-being in racial and ethnic minorities.

Pierre began her laboratory medicine career in her home country of Trinidad, where she identified screening gaps based on socioeconomic status. “It’s not so much that I chose this topic to present, it’s that it is a primary, core focus of the work that I do every day,” she said.

Social unrest in 2020 pushed issues of health equity to the forefront, and Pierre wants to keep pushing forward toward change. “The current social climate tells us why we need to keep paying attention to underprivileged populations, regardless of what identity that person has that makes them underserved or disadvantaged,” Pierre said.

The session will explore how laboratorians can equip themselves to deal with this complex health dilemma and provide foundational and up-to-date information to empower participants to identify the health impacts of structural racism. The speakers also will offer tools to mitigate these impacts and achieve health equity through laboratory medicine and clinical practice workflows.

The session also will present new recommendations from AACC and the National Kidney Foundation on improving equity in kidney disease. This is an important topic in health equity because early detection of kidney disease can lead to interventions that significantly slow down disease progress, Pierre said.

However, most early kidney disease detection happens in a primary care setting, and people who don’t have a primary care physician may be missed, she noted. “How do we ensure that we are optimizing healthcare across the board and not just for a particular group?”

For example, clinical laboratorians can play a role in examining how to use electronic health records to increase the uptake of screening or support physicians on utilizing kidney screening tests, she added.

Panelist Astor Davis is a member of the U.S. Preventive Services Task Force, and will speak to guidance aimed at mitigating systemic racism in guideline development and clinical preventative services. She will discuss how screening guidelines can be adopted to offer a national, unified approach to ensuring preventative testing and care for all. Peck Palmer will also be discussing how to develop a health equity program within both a clinical laboratory and medical institution.

Pierre believes that the panel will be of interest to medical professions across industries, including those working in patient care, clinical laboratory scientists, laboratory directors, and point-of-care coordinators. “My hope is that we can keep a central focus on health equity and make it a part of what we do in our day to day lives,” she said. “People often view health equity as a special mindset, topic, or area of study. But if we have identified groups of patients who have poorer outcomes, then we’re never going to achieve progress if we don’t address the contributing factors to those groups experiencing poorer health outcomes.”

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
PSA Test
Humasis PSA Card
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.